Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. ALGS
ALGS logo

ALGS

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

ALGS News

Aligos Therapeutics Q1 Earnings Beat Expectations

3d agoseekingalpha

Aligos Therapeutics Grants Stock Options to New Employees

Apr 24 2026NASDAQ.COM

Aligos Grants 10,700 Stock Options to New Employees

Apr 24 2026Newsfilter

Aligos Licenses Hepatitis B Drug to Xiamen Amoytop, Secures $25M Upfront

Apr 16 2026stocktwits

Aligos Enters Exclusive Licensing Agreement with Xiamen Amoytop Biotech

Apr 16 2026seekingalpha

Aligos Enters Exclusive License Agreement with Amoytop

Apr 16 2026Newsfilter

Aligos Therapeutics Reports Positive Interim Results in HBV Study

Apr 15 2026NASDAQ.COM

Aligos Receives FDA Fast Track Designation for Pevifoscorvir Sodium

Apr 14 2026Newsfilter

Aligos Therapeutics Reports 2025 Financial Progress and Pipeline Advancements

Mar 06 2026NASDAQ.COM

Aligos Therapeutics Q4 Earnings Beat Expectations

Mar 05 2026seekingalpha

Onco3R Appoints Lawrence Blatt as Board Chair to Drive Growth

Jan 08 2026Globenewswire

Aligos Grants 14,100 Stock Options to New Employees Under Inducement Plan

Dec 12 2025Globenewswire

Aligos Grants 14,100 Stock Options to New Employees as Inducement

Dec 12 2025Newsfilter

Aligos Therapeutics Presents Positive HBV and Weight Loss Data at HEP-DART 2025

Dec 11 2025Newsfilter

Aligos Therapeutics Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)

Oct 17 2025Newsfilter

Biotech Stocks Surge After Hours Due to Trial Advancements, Funding Developments, and Anticipated Milestones

Sep 17 2025NASDAQ.COM